A First-in-Human Study of Mutant-Selective PI3K Inhibitor, RLY-2608, as a Single Agent in Advanced Solid Tumor Patients and in Combination with Fulvestrant in Patients with Advanced Breast Cancer
Study of RLY-2608 in Patients with Breast Cancer
Sponsor: Relay Therapeutics, Inc
Enrolling: Male and Female Patients
IRB Number: AAAU0704
U.S. Govt. ID: NCT05216432
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: This research study is designed to learn about the safety of an experimental (investigational) drug called RLY-2608, also called the study drug, when given to individuals who have been diagnosed with metastatic (spread to other areas of the body) or unresectable (cannot be removed surgically) cancers and have at least one mutation in a gene called PIK3CA. Investigational means that it is not yet known if this drug helps patients, has not been approved by the Food and Drug Administration (FDA) or any other regulatory agency, and is not available for sale as a marketed product. Patients with advanced breast cancer will also receive Fulvestrant in combination with RLY-2608.
Julia McGuinness, MD
Do You Qualify?
Are you at least 18 years old? Yes No
Are you currently breastfeeding? Yes No
Are you able to orally swallow medication? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator